32
Participants
Start Date
December 1, 2021
Primary Completion Date
March 21, 2025
Study Completion Date
March 21, 2025
Bintrafusp alfa
Participants who are continuing treatment with bintrafusp alfa and were previously assigned to a bintrafusp alfa dose based on body weight which is (i.e.) milligrams per kilogram (mg/kg) per dose in a parent protocol, will receive an intravenous infusion of bintrafusp alfa at the dose specified based upon the participant's parent protocol once every 2 week or, 2400 mg once every 3 weeks. Participants who are entering the rollover study after discontinuation of treatment in a parent study will receive bintrafusp alfa at a dose of either 1200 or 2400 mg once every 2 weeks or 2400 mg once every 3 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
The Center for Cancer and Blood Disorders a Division of American Oncology Partners of Maryland, P.A., Bethesda
NIH National Institutes of Health/GMB LTIB, Bethesda
Centre Hospitalier de l'Ardenne - PARENT, Libramont
Harbin Medical University Cancer Hospital, Harbin
Universitaetsklinikum Carl Gustav Carus TU Dresden - Medizinische Klinik I, Dresden
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica, Lazio
National Cancer Center Hospital, Chūōku
Saitama Medical University International Medical Center, Hidaka-shi
National Cancer Center Hospital East, Kashiwa-shi
"BHI of Omsk region Clinical Oncology Dispensary - PARENT", Omsk
Gachon University Gil Medical Center, Incheon
Asan Medical Center, Seoul
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Hospital General Universitario Gregorio Marañón, Madrid
Hospital Universitario Ramon y Cajal - Servicio de Oncologia, Madrid
Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica, Valencia
Taichung Veterans General Hospital, Taichung
Chang Gung Memorial Hospital,Linkou, Taoyuan
Adana City Hospital - Parent Account, Adana
Communal Enterprise Volyn Regional Medical Center of Oncology of Volyn Regional Council - Department of Oncochemotherapy, Lutsk
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono Research & Development Institute, Inc.
INDUSTRY